RT Journal Article
SR Electronic
T1 Obesity as a cause of kidney disease – insights from Mendelian randomisation studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.13.20155234
DO 10.1101/2020.09.13.20155234
A1 Xu, Xiaoguang
A1 Eales, James M.
A1 Jiang, Xiao
A1 Sanderson, Eleanor
A1 Scannali, David
A1 Morris, Andrew P.
A1 Guzik, Tomasz J.
A1 Charchar, Fadi J.
A1 Holmes, Michael V.
A1 Tomaszewski, Maciej
YR 2020
UL http://medrxiv.org/content/early/2020/09/14/2020.09.13.20155234.abstract
AB Objective To examine if modifiable anthropometric indices of obesity exert putatively causal effects on different measures of kidney health and disease.Design Conventional observational and Mendelian randomisation study.Setting UK Biobank and international genome-wide association studies.Participants Approximately 300,000 participants of white-British ancestry from UK Biobank and up to 480,000 participants of predominantly European ancestry from genome-wide association studies.Main outcome measures Estimated glomerular filtration, blood urea nitrogen, kidney health index, chronic kidney disease, hypertensive renal disease, renal failure, acute renal failure, other disorders of kidney and ureters, IgA nephropathy and diabetic nephropathy.Results The Mendelian randomisation analysis indicated that increasing values of genetically predicted body mass index (BMI) and waist circumference were causally linked to changes in renal function indices including reduced estimated glomerular filtration and increased blood urea nitrogen in UK Biobank individuals. These associations were replicated using data from CKDGen Consortium individuals. One standard deviation increase in genetically-predicted BMI and waist circumference decreased the relative odds of kidney health index by 14% and 18% (OR=0·86; 95%CI: 0·82-0·92; P=9·18×10-6 for BMI and OR=0·82; 95%CI: 0·75-0·90; P=2·12×10-5 for waist circumference, respectively). Approximately 13-16% of the causal effect of obesity indices on kidney health was mediated by blood pressure. Obesity increased the risk of both acute and chronic kidney disease of several aetiologies including hypertensive renal disease and diabetic nephropathy.Conclusions These findings indicate that obesity is causally linked to indices of renal health and the risk of different kidney diseases. This evidence substantiates the value of weight loss as a strategy of preventing and/or counteracting a decline in kidney health as well as decreasing the risk of renal disease.What is already known on this topic- Several previous studies reported associations between increasing adiposity/obesity and either a decline in kidney function or the increased risk of specific kidney disorders.- High blood pressure and diabetes represent the two most common aetiologies of chronic kidney disease and co-exist with obesity.- It is not clear to what extent these associations may reflect cause-effect relationships.What this study adds- Our results show a consistent pattern of causation between obesity and kidney health and disease, across different biochemical parameters of kidney function and a broad spectrum of kidney health/disease.- We further demonstrate that the causal effect of obesity on kidney health is partially mediated by blood pressure and largely independent of type 2 diabetes.- We provide evidence for a causal relationship between two clinical indices of obesity and specific renal disorders including hypertensive renal disease, acute renal failure, chronic kidney disease and diabetic nephropathy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by British Heart Foundation project grants PG/17/35/33001 and PG/19/16/34270 and Kidney Research UK grant RP_017_20180302 to MT. Access to UK Biobank data has been through approved project (46114). MVH works in a unit that receives funding from the UK Medical Research Council and is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/23/33512) and the National Institute for Health Research Oxford Biomedical Research Centre. TJG is supported by the European Research Council [ERC and InflammaTENSION; ERC-CoG-726318] and the National Centre for Research and Development of Poland (ERA-Net-CVD PlaqueFIGHT).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Only publicly available anonymised data sets were used. No approval was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings from these investigations are available within the article and the supplementary data files or are available upon reasonable request to the authors.